This Article Full Text Full Text (PDF) Additional Materials All Versions of this Article: 28/4/705    most recent ATVBAHA.107.155333v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Payeli, S.K. Articles by Tanner, F.C. Search for Related Content PubMed PubMed Citation Articles by Payeli, S.K. Articles by Tanner, F.C.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:705.)
© 2008 American Heart Association, Inc.

Cell Biology/Signaling

Prothrombotic Gene Expression Profile in Vascular Smooth Muscle Cells of Human Saphenous Vein, but Not Internal Mammary Artery

S.K. Payeli; R. Latini; C. Gebhard; A. Patrignani; U. Wagner; T.F. Lüscher; F.C. Tanner

From Cardiovascular Research, Physiology Institute (S.K.P., R.L., C.G., T.F.L., F.C.T.), the Center for Integrative Human Physiology (S.K.P., R.L., C.G., T.F.L., F.C.T.), and the Functional Genomics Center Zurich (A.P., U.W.), University of Zurich, and Cardiology (C.G., T.F.L., F.C.T.), Cardiovascular Center, University Hospital Zurich, Switzerland.

Correspondence to Felix C. Tanner, MD, Cardiovascular Research, Physiology Institute, University of Zurich and Cardiology, Cardiovascular Center, University Hospital Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. E-mail felix.tanner{at}access.uzh.ch

Background— The resistance of internal mammary artery (IMA) toward thrombotic occlusion and accelerated atherosclerosis is not well understood. This study analyzed gene expression profiles of vascular smooth muscle cells (VSMCs) from IMA versus saphenous vein (SV).

Methods and Results— 54'675 probe sets were examined by Affymetrix microarrays. Thirty-one genes belonged to the coagulation system; 2 were differentially expressed, namely tissue factor (TF) and tissue-type plasminogen activator (tPA). TF was 3.1-fold lower in IMA than SV (P=0.006), whereas tPA was 9.0-fold higher (P<0.001). TF mRNA expression was lower in IMA than SV (P<0.05); tPA was higher (P<0.001). TF protein expression was 4.2±0.5-fold lower in IMA than SV (P<0.001); tPA was 2.6±0.4-fold higher (P<0.01). In IMA VSMC supernatant, TF protein and activity was lower (P<0.05), TFPI and tPA protein higher (P<0.05 and P<0.005), and clotting time of human plasma prolonged (P<0.05) as compared to SV. Migration to TF/FVIIa (10^–9 mol/L) was 3-fold lower in IMA than SV (P=0.01); PAR-2 protein expression was similar (P=NS), PAR-2 blockade without effect (P=NS).

Conclusions— Among the genes of the coagulation system, TF and tPA are differentially expressed in VSMCs from IMA versus SV. This is consistent with protection of IMA from thrombus formation and vascular remodeling.

Expression profiles of coagulation genes were analyzed by Affymetrix microarrays in vascular smooth muscle cells from internal mammary artery (IMA) versus saphenous vein (SV). TF expression was lower in IMA than SV, whereas tPA was higher. This pattern is consistent with protection of IMA from thrombus formation and vascular remodeling.

Key Words: bypass graft disease • tissue factor • tissue plasminogen activator • coagulation • migration